Astria Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Astria Therapeutics reports increased net loss in Q3 2025, driven by R&D for Navenibart and STAR-0310, while progressing towards a BioCryst merger and securing a Japan licensing deal.
Astria Therapeutics reported increased losses in Q2 2025 but highlighted significant clinical progress for its lead drug candidates, navenibart and STAR-0310, and extended its cash runway into 2028 through a new licensing deal.
Astria Therapeutics reports a net loss of $33.7 million for Q1 2025, driven by increased research and development expenses, while progressing its navenibart and STAR-0310 clinical programs.
Astria Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical programs for navenibart and STAR-0310.
10-Q: Astria Therapeutics Reports Promising Clinical Trial Data and Outlines Future Development Plans
Astria Therapeutics' Q2 2024 report highlights positive clinical trial results for their lead drug candidate, navenibart, and outlines plans for further development of their pipeline.
Astria Therapeutics reported a net loss of $19.9 million for the first quarter of 2024, while highlighting progress in its clinical programs for STAR-0215 and STAR-0310.